Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein

Richard G. Lee, Wuxia Fu, Mark J. Graham, Adam E. Mullick, Donna Sipe, Danielle Gattis, Thomas A. Bell, Sheri Booten, and Rosanne M. Crooke
Cardiovascular Antisense Drug Discovery Group, Isis Pharmaceuticals, Carlsbad, CA 92010

Abstract  Therapeutic agents that suppress apolipoprotein B (apoB) and microsomal triglyceride transfer protein (MTP) levels/activity are being developed in the clinic to benefit patients who are unable to reach target LDL-C levels with maximally tolerated lipid-lowering drugs. To compare and contrast the metabolic consequences of reducing these targets, murine-specific apoB or MTP antisense oligonucleotides (ASOs) were administered to chow-fed and high-fat fed C57BL/6 or to chow-fed and Western diet-fed LDLr−/− mice for periods ranging from 2 to 12 weeks, and detailed analyses of various factors affecting fatty acid metabolism were performed. Administration of these drugs significantly reduced target hepatic mRNA and protein, leading to similar reductions in hepatic VLDL/triglyceride secretion. MTP ASO treatment consistently led to increases in hepatic triglyceride accumulation and biomarkers of hepatotoxicity relative to apoB ASO due in part to enhanced expression of peroxisome proliferator activated receptor γ target genes and the inability to reduce hepatic fatty acid synthesis. Thus, although both drugs effectively lowered LDL-C levels in mice, the apoB ASO produced a more positive liver safety profile.—Lee, R. G., W. Fu, M. J. Graham, A. E. Mullick, D. Sipe, D. Gattis, T. A. Bell, S. Booten, and R. M. Crooke. Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein. J. Lipid Res. 2013. 54: 602–614.

Supplementary key words  microsomal triglyceride transfer protein • dyslipidemia • steatosis • lipoprotein metabolism • lipid droplets • familial hypercholesterolemia

Coronary heart disease is the leading cause of death in the United States (1). Although multiple risk factors associated with this disease process are being extensively investigated, it is well established that lowering plasma LDL cholesterol (LDL-C) reduces cardiovascular risk events (2). The most effective therapeutic agents for the treatment of elevated LDL-C levels and, ultimately, coronary heart disease are the statins (3). Although these drugs have proven to be potent and efficacious, a significant percentage of high-risk patients are unable to attain their ATP-III recommended LDL-C goals for several reasons, including ineffectiveness or intolerance to statins alone or in combination with other dyslipidemia agents (4, 5). These factors have led to a continued search for new drugs with unique mechanisms of action that lower plasma LDL-C levels.

Two proteins involved in the formation of apoB-containing lipoprotein particles that have recently received considerable attention as potential therapeutic targets are apolipoprotein B (apoB) and microsomal triglyceride transfer protein (MTP) (6–8). Both are essential for the assembly and secretion of the apoB-containing lipoproteins (i.e., VLDL) synthesized in the liver and chylomicrons produced by enterocytes of the small intestine. In the liver, apoB100 is the main structural protein component of VLDL and LDL particles.

Extensive biochemical studies indicate that apoB protein is primarily regulated at the post-transcriptional level (9). Initially, nascent apoB protein is transferred through the ER membrane and into the ER lumen. In the absence of sufficient lipid or functional MTP, apoB fails to be lipidated and undergoes retrograde translocation into the cytosol, where it is ubiquitinated and degraded. However, in the presence of sufficient lipid, apoB is lipidated in an MTP-dependent, two-step process, leading to the formation and secretion of a mature VLDL particle (10). VLDL then enters the circulation and is acted upon by lipolytic and lipoprotein transfer enzymes that convert triglycerides TG-rich

Abbreviations: ACC1, acetyl-coA carboxylase 1; ALT, alanine aminotransferase; ASO, antisense oligonucleotide; AST, aspartate aminotransferase; CE, cholesteryl ester; FSP27, fat-specific protein 27; HB, β-hydroxybutyrate; MTP, microsomal triglyceride transfer protein; PPARγ, peroxisome proliferator activated receptor γ; TG, triglyceride; WW, wet weight.

1 To whom correspondence should be addressed.
e-mail: rlee@isisph.com

All studies were funded by Isis Pharmaceuticals.
Manuscript received 12 June 2012 and in revised form 29 November 2012
Published, JLR Papers in Press, December 6, 2012
DOI 10.1194/jlr.M029215

Copyright © 2013 by the American Society for Biochemistry and Molecular Biology, Inc.
were synthesized and purified on an automated DNA synthesizer and 1–5 and 15–20 targeted to murine apoB, MTP, and a control ASO.

Mice

C57BL/6 and LDLr/H11002 mice. However, experiments directly comparing the therapeutic reduction of apoB and MTP have not been possible because apoB is not targetable by small molecule approaches. Therefore, to perform such studies, we designed an ASO to murine MTP and directly compared its activity with that of an apoB antisense drug, ISIS 147764 (11), in preclinical pharmacology models.

Pharmacological suppression of hepatic apoB production via antisense oligonucleotide (ASO) treatment has also led to reductions in VLDL-C and LDL-C and the amelioration of atherosclerosis in murine preclinical models (11, 12). Furthermore, although a murine-specific apoB ASO reduced apoB production and secretion from the liver, hepatic steatosis and elevation of transaminases were not observed in these mice (11). In high fat-fed mice administered the apoB ASO, liver TG accumulation was shown to be reduced as a result of secondary, compensatory mechanisms that lead to reduced lipogenesis and increased fatty acid oxidation. Additionally, there were no effects on dietary fat absorption, chylomicron formation, or increases in intestinal TG accumulation due to limited ASO distribution to the small intestine.

Given the importance of MTP to VLDL production, we also wished to evaluate the effects of an inhibitor of MTP in C57BL/6 and LDLr/H11002 mice. However, experiments directly comparing the therapeutic reduction of apoB and MTP have not been possible because apoB is not targetable by small molecule approaches. Therefore, to perform such studies, we designed an ASO to murine MTP and directly compared its activity with that of an apoB antisense drug, ISIS 147764 (11), in preclinical pharmacology models.

MATERIALS AND METHODS

Antisense oligonucleotides

A series of uniform chimeric 20-mer phosphorothioate oligonucleotides containing 2′-O-methoxyethyl groups at positions 1–5 and 15–20 targeted to murine apoB, MTP, and a control ASO were synthesized and purified on an automated DNA synthesizer using phosphoramidite chemistry as previously described (13). The sequences evaluated were as follows: apoB ASO-ISIS 147764 (5′-GTCCCTTGAGATGTCAGTGTC-3′), MTP ASO-ISIS 144477 (5′-GCCAGCACCTGGTTTCGCGT-3′), and one of two control ASOs-ASO 1 (5′-AGGAGTTAAGCGAGCTCCC-3′) or ASO 2 (5′-AGCATAGTTAAGCGAGCTCCC-3′), with underlining indicating 2′-O-methoxyethyl-modified bases.

Mice

Six week old male C57BL/6 or LDLr/H11002 (Jackson Laboratory) mice in cages (n = 3–5 per cage) on a 12-h light-dark cycle for the duration of the studies. All procedures and protocols were approved by an institutional animal care and use committee. C57BL/6 mice were fed chow or a high-fat diet (60% calories as fat; Research Diets D12492) (DIO model) for 3 weeks. After the diet acclimation period, mice were randomized based on TPC and nonHDL-C and then administered assigned ASOs in saline (5 mg/ml) by intraperitoneal injection at a dose of 25, 12.5, or 6.25 mg/kg twice weekly for 2 or 6 weeks. LDLr/H11002 mice were fed a standard chow diet or a Western diet (Harland Teklad Diet 88137) consisting of 42% of calories as fat and 0.15% cholesterol for 1 week. The mice were then bled, randomized based on TPC and nonHDL-C, and administered control ASO (50 mg/kg/week), apoB ASO (50 mg/kg/week), or MTP ASO (50 mg/kg/week) for periods ranging from 2 to 12 weeks while remaining on diet. For 12 week studies, mice received intraperitoneal injections of ASO once weekly for 6 weeks and then once every other week for the remainder of the study. Body weight was monitored throughout the study, with no significant differences between control and treated mice observed in any of the studies. At the end of treatment period, animals were fasted for 4 h and euthanized for blood and tissue analysis.

Plasma chemistry and lipoprotein cholesterol analysis

Plasma lipids and aminotransferase concentrations were quantified on an Olympus AU400e automated clinical chemistry analyzer (Melville, NY). HPLC analysis of LDLr/H11002 mice cholesterol distribution among VLDL-C, LDL-C, and HDL-C fractions was performed as described previously. Percent area under curve VLDL-C, LDL-C, and HDL-C was determined using Peakfit™ v 4.12 (Seasolve Software®, Framingham MA) and then multiplied by TPC to determine VLDL-C, LDL-C, and HDL-C, respectively.

Histology

Oil Red O (ORO) staining on sections of snap-frozen liver and intestinal samples was performed as described (14). For quantitation of lipid droplets, digital 10× (1,700 x 1,100 μm) images (four images per treatment group, with each image taken from a different mouse) of ORO-stained sections were analyzed with the ChromaColor™ software to identify all ORO-stained droplets. Those densitometric images were quantified using Image Pro Plus™ software, which sorted the droplets into one of four sizes: 5–50 μm², 51–100 μm², 101–1,000 μm², or >1,000 μm², with the largest size class considered to be an artifact of the staining procedure.

Tissue lipid composition

Liver TG, free cholesterol, and total cholesterol were extracted and analyzed as described previously (15). Intestinal lipid was quantitated after fasting the mice for 4–5 h. Mice were then euthanized, and the small intestine from the pyloric valve to the cecum was collected and divided into three equal pieces. The luminal contents were flushed with PBS from the proximal section, and each section was cut longitudinally with scissors and flattened, and the mucosal layer was scraped off with a glass slide. An aliquot of the cells was suspended in PBS. One-fifth of the suspension was brought to 1 N NaOH for protein determination by the Lowry method, and three-fifths of the lipid was extracted by the Bligh-Dyer method described previously. The extract was solubilized with 2% Triton ×100 in dH2O, and lipids were quantified using colorimetric assays as described for the liver lipid extraction.

MTP activity assay

Aliquots of livers isolated from DIO mice treated with ASO for 6 weeks were snap frozen and sent to Chylos® Inc. (New York,
Quantitative real-time PCR

Real-time PCR was performed as described (11). Sequences of the primer probe sets used are provided in supplementary Table I. All data were normalized to cyclophilin A mRNA levels and were expressed as percent of hepatic mRNA expression in control ASO-treated mice.

Statistical analysis

The majority of pharmacology experiments were performed in at least two independently performed studies with groups of 4 to 12 animals. All values are expressed as mean ± SEM. To determine statistical significance, one- and two-way ANOVA analysis with Tukey’s post hoc test was carried out using GraphPad Prism 5™ software with statistical significance being set at $p < 0.05$.

RESULTS

Second-generation ASOs targeting murine apoB (ISIS 147764), whose pharmacology has been described in detail in two previous studies (11, 12), or MTP (ISIS 144477), which in primary mouse hepatocytes reduced MTP mRNA

Quantitation of TG and cholesterol absorption

DIO mice administered ASO for 6 weeks were fasted overnight and then received an intraperitoneal injection of poloxamer 407 at a dose of 1 mg/g body weight. One hour after injection, a baseline retro-orbital bleed was collected, and the mice were orally gavaged with 2.5 μCi of $^3$H triolein in 200 μl of olive oil. Animals were bled 90 and 180 min after gavage, and counts per minute (cpm) values were quantified from 20 μl of serum by liquid scintillation counting (LSC Instrument; Beckman). Cholesterol absorption in DIO mice treated with ASO for 6 weeks was quantitated using the dual fecal isotope method as described previously (17).

Hepatic ApoB and TG secretion

Hepatic and apoB secretion was carried out as previously described (18).

Analysis of hepatic fatty acid synthesis

Quantitation of hepatic fatty acid synthesis was carried out using the tritiated water method described previously (19).

Fig. 1. ApoB and MTP ASOs reduce liver target mRNA expression in three different mouse models. Chow-fed (n = 5–8 per group) (A) or DIO C57BL/6 mice (n = 4) (B) were administered ASO for 2 or 6 weeks. C: Chow-fed or Western diet-fed LDLr-/- mice were administered ASO for 6 weeks. Quantitative RT-PCR was carried out as described in Materials and Methods. Number on x axis indicates mg/kg/week dose. *Significantly different ($P < 0.05$) when compared with control ASO. †Significantly different when compared with MTP ASO treatment.
in a dose-dependent manner (supplementary Fig. 1), were used for all studies. To compare the pharmacological effects of apoB and MTP ASOs on safety, efficacy, and hepatic steatotic progression, three mouse models were used. Initially, ASOs were administered to chow-fed C57BL/6 mice twice weekly (12.5–50 mg/kg/week) for 2 or 6 weeks to assess their efficacy and tolerability. To further investigate the effects on liver TG accumulation between apoB and MTP ASO treatment, the two compounds were administered to DIO mice, a model of hepatic steatosis, for 2 or 6 weeks. Finally, because the severe familial hypercholesterolemia patient population is the primary indication for apoB and MTP drugs, male LDLr⁻/⁻ mice were fed chow or Western diets and administered ASOs at 50 mg/kg/week for 6 weeks.

In all three mouse models, ASO administration led to significant, dose-dependent suppression of hepatic target mRNA expression, reaching 70% to 90% reduction when compared with control ASO-treated animals at the high dose after 6 weeks of treatment (Fig. 1). Consistent with the mRNA data, DIO and LDLr⁻/⁻ mice treated with the apoB ASO-demonstrated reductions in hepatic target protein levels when compared with control ASO treatment (Fig. 2). The MTP ASO-treated DIO and LDLr⁻/⁻ reductions in hepatic target protein were also consistent with the degree of hepatic MTP mRNA suppression. Furthermore, measurement of hepatic MTP activity in DIO mice after 6 weeks of MTP ASO treatment showed that the reduction in activity (−71%) was consistent with the hepatic MTP mRNA and total protein reductions (Fig. 2C). Administration of the apoB ASO significantly increased MTP activity by 25% when compared with control.

As expected, reduction of hepatic apoB and MTP led to significant reductions in TPC in the DIO mice and LDLr⁻/⁻ mice fed chow or Western diet (Tables 1 and 2). In DIO mice (Table 1), the reductions in TPC were due to reductions in nonHDL-C and HDL-C, a plasma lipid profile that is similar to that observed in ApoB⁻/⁻ or MTP⁻/⁻ mice (20, 21). In addition, neither apoB nor MTP ASO had any effect on plasma TG, which was not surprising given the relatively low plasma TG levels of this model. However, apoB and MTP ASO treatment significantly decreased plasma TG in Western diet-fed LDLr⁻/⁻ mice by −69% and −75%, respectively (Table 2). More detailed evaluation of plasma samples taken from apoB and MTP ASO-treated LDLr⁻/⁻ mice indicated that the TPC and plasma TG reductions were primarily due to decreases in apoB-containing lipoproteins; however, there was a significant decrease (−30%) in HDL-C in the chow-fed LDLr⁻/⁻ mice (Table 2). For VLDL, similar reductions were observed for apoB ASO (−58% for chow, −82% for Western diet) and MTP ASO (−71% for chow, −85% for Western diet) treatment. However, LDL-C was reduced to a greater extent by apoB ASO (−61% for chow, −73% for Western diet).
diet) versus MTP ASO (−40% for chow, −42% for Western diet) administration. Therefore, in DIO and LDLr−/− mouse models, 6 weeks of treatment with the apoB or MTP ASOs led to significant reductions in hepatic apoB or MTP protein that in turn led to decreased plasma TPC and, in a severely hyperlipidemic model, decreased plasma TG.

Suppression of intestinal expression of apoB or MTP can reduce lipid absorption and potentially lower plasma lipid levels by impairing intestinal secretion of apoB48-containing chylomicron particles. To determine if the amelioration of dyslipidemia observed with ASO treatment was due to alterations in intestinal metabolism, lipid absorption (Fig. 3) was quantified. Dietary food intake and animal body weights were unaffected by apoB or MTP ASO treatment; nor was there evidence of steatorrhea/loose stools (data not shown). Proximal intestinal apoB mRNA expression was unchanged after 2 weeks of apoB ASO treatment but was significantly reduced by 62% after 6 weeks (Fig. 3A). Intestinal apoB48 protein also appeared to be reduced, albeit more modestly than the apoB mRNA expression, with 6 weeks of ASO treatment (Fig. 3B).

However, due to the weak and variable apoB48 protein bands, it is difficult to draw a distinct conclusion from the Western blot results. After 2 and 6 weeks of treatment, the MTP ASO led to significant reductions of −50% and −59% in proximal SI MTP mRNA expression, respectively. Unlike the apoB ASO, the MTP ASO had little to no effect on intestinal MTP protein expression and increased apoB48 protein expression. The reduced efficacy of the ASOs relative to liver was expected based on the observation in previous studies of limited distribution of ASO (22) to the intestine.

To determine if the reduction of intestinal apoB and MTP led to physiologic effects on lipid and sterol absorption, we measured TG and cholesterol absorption in DIO mice treated with ASOs for 6 weeks (Fig. 3C). Poloxamer 407-treated mice were administered a tritiated triolein gavage, and the appearance of radioactivity was quantitated over a 3 h period. ApoB ASO-treated animals had a modest, but significantly reduced, secretion of tritiated triolein into the plasma (−30%) at the 3 h time point when compared with control ASO. The MTP ASO also showed a

### Table 1. Plasma lipids, ALT, AST, and 3HB levels in DIO C57BL/6 mice administered ASOs for 2 or 6 weeks

|                | ALT (U/L) | AST (U/L) | TPC (mg/dl) | Non-HDL-C (mg/dl) | HDL-C (mg/dl) | Plasma TG (mg/dl) | Plasma 3HB (mmol/l) |
|----------------|-----------|-----------|-------------|-------------------|---------------|-------------------|---------------------|
| 2 week DIO C57BL/6 |           |           |             |                   |               |                   |                     |
| Control ASO (50) | 33 ± 4    | 56 ± 4    | 169 ± 12    | 25 ± 2            | 137 ± 10      | 95 ± 2            | 274 ± 28            |
| ApoB ASO (50)    | 71 ± 9    | 60 ± 4    | 92 ± 2a     | 12 ± 1a           | 79 ± 1b       | 73 ± 7            | 514 ± 42a           |
| ApoB ASO (25)    | 74 ± 24   | 101 ± 18  | 144 ± 9     | 20 ± 2            | 118 ± 7       | 93 ± 9            | 294 ± 66            |
| ApoB ASO (12.5)  | 41 ± 1    | 53 ± 5    | 148 ± 6     | 22 ± 1            | 119 ± 4       | 85 ± 3            | 336 ± 27            |
| MTP ASO (50)     | 243 ± 30a | 172 ± 29e | 143 ± 11    | 23 ± 2            | 114 ± 9       | 65 ± 4            | 484 ± 48e           |
| MTP ASO (25)     | 81 ± 9    | 89 ± 6    | 145 ± 4     | 21 ± 1            | 117 ± 4       | 79 ± 9            | 499 ± 72e           |
| MTP ASO (12.5)   | 45 ± 7    | 61 ± 3    | 176 ± 5     | 24 ± 1            | 140 ± 4       | 72 ± 2            | 437 ± 43            |
| 6 week DIO C57BL/6 |           |           |             |                   |               |                   |                     |
| Control ASO (50) | 41 ± 5    | 76 ± 17   | 161 ± 30    | 31 ± 2            | 129 ± 18      | 99 ± 3            | 251 ± 32            |
| ApoB ASO (50)    | 62 ± 26   | 59 ± 9    | 72 ± 1a     | 12 ± 0.2a         | 64 ± 1a       | 78 ± 11           | 355 ± 53            |
| ApoB ASO (25)    | 50 ± 13   | 65 ± 9    | 91 ± 6b     | 13 ± 1a           | 79 ± 6e       | 94 ± 3            | 372 ± 89            |
| ApoB ASO (12.5)  | 47 ± 18   | 51 ± 5    | 140 ± 1     | 26 ± 1            | 116 ± 1       | 95 ± 8            | 334 ± 32            |
| MTP ASO (50)     | 349 ± 75a | 184 ± 40e | 114 ± 10b   | 23 ± 2            | 95 ± 7        | 70 ± 2            | 580 ± 64e           |
| MTP ASO (25)     | 96 ± 25   | 76 ± 6    | 102 ± 8e    | 22 ± 2e           | 84 ± 7e       | 80 ± 2            | 484 ± 53            |
| MTP ASO (12.5)   | 89 ± 26   | 82 ± 17   | 126 ± 4     | 26 ± 2            | 105 ± 5       | 83 ± 4            | 383 ± 56            |

Values represent mean ± SEM (n = 4 per group). Number in parentheses indicates mg/kg/week dose.

### Table 2. Plasma lipids, ALT, and AST levels in chow-fed or Western diet-fed LDLr−/− mice administered ASOs for 6 weeks

|                | ALT (U/L) | AST (U/L) | TPC (mg/dl) | VLDL-C (mg/dl) | LDL-C (mg/dl) | HDL-C (mg/dl) | Plasma TG (mg/dl) |
|----------------|-----------|-----------|-------------|----------------|---------------|---------------|-------------------|
| 6 week chow-fed LDLr−/− mice |           |           |             |                |               |               |                   |
| Control ASO (50) | 29 ± 1    | 66 ± 6    | 348 ± 24    | 17 ± 2.6       | 235 ± 15      | 97 ± 14       | 156 ± 11          |
| ApoB ASO (50)    | 62 ± 12a  | 78 ± 10   | 167 ± 10a   | 7 ± 1          | 92 ± 7a       | 68 ± 6a        | 82 ± 6a           |
| MTP ASO (50)     | 38 ± 7    | 76 ± 12   | 205 ± 10a   | 5 ± 4          | 140 ± 8a      | 60 ± 3         | 102 ± 6a          |
| 6 week Western diet-fed LDLr−/− mice |           |           |             |                |               |               |                   |
| Control ASO (50) | 92 ± 23   | 139 ± 21  | 1546 ± 50   | 646 ± 42       | 787 ± 14      | 113 ± 9       | 585 ± 25          |
| ApoB ASO (50)    | 149 ± 31a | 128 ± 10e | 407 ± 58a   | 114 ± 35a      | 209 ± 36e     | 84 ± 10        | 182 ± 33a         |
| MTP ASO (50)     | 258 ± 46e | 207 ± 25e | 671 ± 81a   | 98 ± 28e       | 457 ± 57e     | 116 ± 8        | 147 ± 25e         |

Values represent mean ± SEM (n = 8–9 per group). Number in parentheses indicates mg/kg/week dose.

* Significantly different (P < 0.05) compared with MTP ASO-treated mice at the same dose.

<ref>TABLE 1. Plasma lipids, ALT, AST, and 3HB levels in DIO C57BL/6 mice administered ASOs for 2 or 6 weeks</ref>

<ref>TABLE 2. Plasma lipids, ALT, and AST levels in chow-fed or Western diet-fed LDLr−/− mice administered ASOs for 6 weeks</ref>
ApoB vs MTP ASO suppression in mice

A. 2 Week Proximal Intestine ApoB mRNA
   - Control ASO, ApoB ASO, MTP ASO

B. 6 Week Proximal Intestine ApoB mRNA
   - Control ASO, ApoB ASO, MTP ASO

C. 2 Week Intestinal Triglyceride
   - Control ASO, ApoB ASO, MTP ASO

D. 2 Week Intestinal Cholesterol
   - Control ASO, ApoB ASO, MTP ASO

E. 6 Week Proximal Intestine Triglyceride
   - Control ASO, ApoB ASO, MTP ASO

F. 6 Week Proximal Intestine Cholesterol
   - Control ASO, ApoB ASO, MTP ASO

G. H&E and ORO staining
   - Control ASO, ApoB ASO, MTP ASO
nonsignificant tendency (−25%) to reduce tritiated triolein when compared with the control ASO. Neither compound demonstrated a significant effect on cholesterol absorption as measured by the dual fecal isotope method. Proximal intestine histology and lipid content were also analyzed. Consistent with minimal effects on total lipid absorption, there were no significant changes in TG or total cholesterol concentrations when quantitated and compared with the control ASO-treated mice (Fig. 3D); nor were there observable increases in neutral lipid accumulation detected using H&E and ORO staining methods (Fig. 3E).

In two previous publications (11, 12), no reductions were observed in intestinal apoB48 protein levels; nor were there any effects on lipid absorption observed after extended administration of the apoB ASO in the DIO and LDLr−/− mice used in those experiments. However, in this most recent study, a modest but significant reduction in apoB48 levels was noted. Nonetheless, the apparent reduction in apoB48 protein levels did not produce increased intestinal lipid deposition or reduced cholesterol/TG absorption. This variation in the protein modulation may be attributed to differences in mouse progeny, dietary constituents, experimental protocols, or test reagents in studies performed over the last decade.

After demonstration that the apoB and MTP ASO were sufficiently efficacious, we evaluated the safety profile of the two ASOs using a number of parameters (Tables 1–3). Liver TG and CE concentrations were evaluated in chow-fed C57BL/6, DIO, and LDLr−/− mice used in those experiments. However, in this most recent study, a modest but significant reduction in apoB48 levels was noted. Nonetheless, the apparent reduction in apoB48 protein levels did not produce increased intestinal lipid deposition or reduced cholesterol/TG absorption. This variation in the protein modulation may be attributed to differences in mouse progeny, dietary constituents, experimental protocols, or test reagents in studies performed over the last decade.

A markedly different safety profile was observed in the face of a dietary challenge. Two weeks of high-dose (50 mg/kg/week) apoB or MTP ASO treatment in DIO mice led to a significant 3.34-fold elevation in liver TG when compared with controls (Table 3). However, after 6 weeks of apoB ASO administration, hepatic TG concentrations were relatively unchanged from those levels observed after 2 weeks. In contrast, 6 weeks treatment with the MTP ASO resulted in a further 3.2-fold increase in liver TG relative to the 2 week treatment values. Similar to chow-fed mice, DIO mice treated with MTP and apoB ASO showed significant increases in hepatic CE after both 2 and 6 weeks. As in the chow-fed animals, liver free cholesterol was similar in all groups (data not shown). Analysis of hepatic transaminases revealed that, unlike observations made in chow-fed mice, 2 week high-dose MTP ASO treatment significantly increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) by 7.4-fold and 3.1-fold, respectively, when compared with control. Similarly, 6 week high-dose MTP ASO treatment in DIO mice significantly increased plasma ALT and plasma AST by 8.5-fold and 2.4-fold, respectively, when compared with control (Table 1). In contrast, 2 week and 6 week high-dose apoB ASO treatment led to a nonsignificant increase in ALT levels of 2.1- and 1.5-fold, respectively, with no change in AST. Finally, DIO mice dosed at 25 and 12.5 mg/kg/week with the MTP ASO or apoB ASO demonstrated no significant changes in plasma transaminase levels. In chow-fed LDLr−/− mice, only apoB ASO led to significant increases (2.1-fold) in ALT concentrations when compared with controls. As with DIO mice, Western diet-fed LDLr−/− mice treated with the MTP ASO displayed significant increases in plasma ALT and AST concentrations of 2.8-fold and 1.4-fold, respectively, when compared with control (Table 2), whereas apoB ASO treatment tended to increase plasma ALTs by 1.6-fold. Unlike chow and DIO mice, chow-fed LDLr−/− mice dosed with the apoB or MTP ASO showed similar increases in liver TG. In Western diet-fed LDLr−/− mice, apoB ASO significantly increased hepatic TG 2.4-fold, whereas MTP ASO showed a 3.9-fold increase in liver TG that was significantly greater than the apoB ASO and control ASO treatments (Table 3). As with the chow and DIO mice, liver CE was significantly increased to a similar extent with apoB ASO and MTP ASO treatment, and hepatic free cholesterol concentrations did not change with either treatment (data not shown).

Therefore, upon receiving a dietary challenge, DIO and LDLr−/− mice treated with the MTP ASO developed more extensive hepatic steatosis and liver injury, as evidenced by elevated transaminases, when compared with apoB ASO
treatment. Using these models, we attempted to identify the factors that would lead to such differences in the development of steatosis observed between the two targets.

To determine if the discrepancies in hepatic TG accumulation between apoB and MTP ASO treatment were due to differences in VLDL secretion, apoB and TG accumulation was quantitated in ASO-treated mice administered a Triton WR1339/35S methionine bolus (Fig. 4). Our data showed that apoB and MTP ASO administration significantly reduced TG secretion to a similar extent in DIO and Western diet-fed LDLr−/− mice when compared with control. However, quantitation of 35S apoB protein secretion in DIO mice demonstrated that, relative to MTP, the apoB ASO was a more potent inhibitor of apoB48 secretion at the 120 min and at the 180 min time points. The relative insensitivity of apoB48 to MTP suppression has previously (11, 12), we had identified PPARγ and its target genes CD36 and FSP27 as being regulated by apoB ASO treatment significantly reduced hepatic SCD-1 mRNA expression, a key enzyme in the lipogenic pathway (27). After 6 weeks of apoB ASO treatment, DIO mice showed significant reductions in hepatic mRNA expression of peroxisome proliferator activated receptor γ (PPARγ) and protein cofactors. Previous studies have demonstrated that PPARγ can increase lipid droplet size via increased expression of fat-specific protein 27 (FSP27) (26).

Based on microarray data and studies described previously (11, 12), we had identified PPARγ as being regulated by apoB ASO. Quantitation of hepatic mRNA (Table 4) revealed that, although there were no significant differences compared with control ASO, 2 weeks of apoB ASO treatment led to significant decreases in hepatic mRNA expression of PPARγ and PPARγ-regulated genes FSP27 and CD36 as well as the adipocyte-specific marker adipin relative to the MTP ASO. Furthermore, apoB and MTP ASO treatment significantly reduced hepatic SCD-1 mRNA expression, a key enzyme in the lipogenic pathway (27). After 6 weeks of apoB ASO treatment, DIO mice showed significant reductions in hepatic PPARγ mRNA when compared with MTP ASO-treated mice (Table 5). In contrast, the hepatic expression of PPARγ and its target genes CD36 and FSP27, as well as the adipocyte-specific marker adipin, which is more highly expressed with PPARγ overexpression (28), were significantly greater in MTP ASO-treated animals.

Because increased hepatic de novo lipogenesis can contribute to liver TG accumulation, we studied this synthetic process by evaluating transcriptional factors and fatty acid synthesis in mice treated with ASO for 6 or 12 weeks. The differences in liver TG concentrations after 12 weeks of treatment were similar to shorter-duration studies (4.3 mg/g liver wet weight [WW] with control ASO vs. 20.3 mg/g liver WW with apoB ASO vs. 81.7 mg/g liver WW with MTP ASO). DIO mice administered the highest dose of apoB or MTP ASO showed similar reductions in acetylcoA carboxylase 1 (ACCo) mRNA expression (Table 5).
key enzyme involved in fatty acid synthesis. Furthermore, after 6 weeks of ASO treatment, hepatic ACC1 mRNA significantly increased by 66% when compared with control. Hepatic AMPKα2 protein expression was also reduced by both drug treatments, whereas apoB ASO-treated animals showed more pronounced protein reduction relative to MTP ASO treatment (Fig. 6) after 6 weeks of ASO treatment. When hepatic lipogenesis was quantified at 6 and 12 weeks of treatment, this process tended to be reduced at both time points with the apoB ASO, but these changes did not achieve statistical significance ($P = 0.28$ and $P = 0.14$, respectively). MTP ASO treatment tended to suppress lipogenesis at 6 weeks ($P = 0.58$) but had no effect after 12 weeks ($P = 0.96$). Therefore, the differences in TG accumulation between apoB and MTP ASO treatment appear to be due in part to 1) the inability of MTP ASO-treated animals after long-term treatment to suppress lipogenesis, 2) the development of larger lipid droplets with the MTP ASO, and 3) reduced PPARγ pathway mRNA expression produced by apoB ASO relative to the MTP ASO.

Another potential contributing factor to hepatic steatosis is reduced fatty acid oxidation. An accepted in vivo biomarker for fatty acid oxidation is 3-hydroxybutyrate (3HB) (29). In DIO mice treated for 2 weeks, plasma 3HB levels were significantly increased with apoB and MTP ASO treatment (Table 1), indicating that these animals were compensating for elevated levels of hepatic TG levels by increasing fatty acid oxidation. However, after 6 weeks of treatment, 3HB levels remained elevated only with MTP ASO treatment, possibly because apoB ASO-treated mice no longer had elevated liver TG concentrations.

### DISCUSSION

Given that antisense drugs share similar pharmacokinetic properties and distribute predominantly in the liver

---

**Fig. 4.** Hepatic ApoB and TG secretion in ApoB-treated or MTP ASO-treated (50 mg/kg/week) DIO mice. Fasted DIO mice (n = 4 per treatment group) were injected with a $^{35}$S Met/Triton WR1339 bolus. Animals were bled at the 60, 120, and 180 min time points, and apoB-100, apoB-48, and TG levels were analyzed. A: TG levels at each time point were determined by colorimetric assay in control ASO (square with dashed line), apoB ASO (diamond with solid line), and MTP ASO-treated mice (triangle with dashed line) (left panel) and Western diet-fed LDLr$^{-/-}$ mice (right panel). B: Plasma (5 μl) from the 120 and 180 min time points were analyzed by SDS-PAGE. The gels were dried down and exposed to film. C: Films were scanned and densitometry on the apoB100, and apoB48 bands were assessed for control ASO-treated (gray bars), apoB ASO-treated (black bars), and MTP ASO-treated (hatched bars) mice. Bars represent mean; error bars represent SEM. $^\# P < 0.05$ when compared with control ASO. $^\$ Significantly different ($P < 0.05$) when compared with MTP ASO treatment.
Fig. 5. Effects of ApoB and MTP ASO (50 mg/kg/week) on liver lipid droplets in DIO mice. A: Representative images of H&E- and ORO-stained liver sections from DIO mice treated for 2 weeks with control ASO (50 mg/kg/week), apoB ASO (50 mg/kg/week), or MTP ASO (50 mg/kg/week). B: Representative images of H&E- and ORO-stained liver sections from DIO mice treated for 6 weeks with control ASO (50 mg/kg/week), apoB ASO (50 mg/kg/week), or MTP ASO (50 mg/kg/week). ORO-stained sections were counterstained with hematoxylin. C: Quantitation of lipid droplet number and size distribution in DIO mice administered ASO for 2 or 6 weeks. ORO-stained liver
As described previously and shown herein, AMPKα mRNA levels were increased after apoB ASO treatment (Table 5). An established method to detect hepatic β oxidation is to evaluate 3HB, or ketone levels, in vivo (32, 33). Using that technique, it appeared that 3HB was increased in apoB ASO-treated DIO mice after 2 weeks of treatment (Table 1), when liver TG levels were elevated in comparison to controls (Table 3), but after 6 weeks, when hepatic TG levels were similar to controls, 3HB levels returned to those observed in control ASO-treated mice. This was in contrast to MTP ASO-treated animals, which had elevated plasma TG and 3HB levels and at the highest administered dose and increased transaminase levels at both the 2 week and 6 week time points. Sustained fatty acid oxidation has been shown to increase reactive oxygen species, which, through many well documented pathways, including the peroxidation of polyunsaturated fatty acids, leads to enhanced oxidative stress, thus potentially contributing to the development of liver injury (30).

In MTP ASO-treated mice, many lipogenic genes were also down-regulated, with similar reductions as observed in apoB ASO-treated mice such as SCD-1, whereas less robust down-regulation was demonstrated for ACC1. Finally, AMPKα levels were unaffected by MTP ASO treatment. Regardless of these reductions in lipogenic genes, de novo fatty acid synthesis, as determined using tritiated water, was not significantly reduced in MTP-treated mice (Fig. 6), perhaps due to more modest effects on ACC1 mRNA and protein. ACC1 is a key enzyme that catalyzes the synthesis of malonyl CoA and plays a pivotal role in de novo lipogenesis and mitochondrial fatty acid oxidation (34). These observations suggest that blocking VLDL secretion with an MTP or apoB ASO may trigger common metabolic pathways to compensate for increased hepatic TG deposition, including down-regulation of lipogenesis and increased β-oxidation. These adaptive processes have also been observed in mice with a targeted apoB38.9 mutation (35) and in hepatocytes isolated from humans with familial hypobetalipoproteinemia (36).

Another potential contributor to the consistent hepatic steatosis observed in MTP mice but not in apoB ASO-treated mice relates to differential effects upon PPARγ-regulated genes that are thought to be involved in lipid droplet formation and homeostasis. We observed key differences between apoB and MTP ASO treatment in lipid droplet size (Fig. 5) and the expression of PPARγ and FSP27 genes (Tables 4 and 5) previously implicated in lipid droplet metabolism. Others have shown that FSP27, a lipid droplet associated protein, is integral to the PPARγ-dependent development of hepatic steatosis in mice (37). In vitro evidence indicates that FSP27 overexpression results in TG accumulation and increased lipid droplet size in AML12 cells, primary hepatocytes (37), and COS cells due in part to decreases in fatty acid oxidation and TG turnover. Furthermore, recent in vivo experiments demonstrated

### Table 4. Hepatic mRNA expression of a subset of key metabolic genes after 2 weeks of 50 mg/kg/week ASO treatment in DIO mice

| Week 2                  | Control ASO | ApoB ASO | MTP ASO |
|------------------------|-------------|----------|---------|
| Fatty acid metabolism  |             |          |         |
| SREBP1-c               | 100 ± 12    | 36 ± 6   | 40 ± 9  |
| ACC1                   | 100 ± 17    | 57 ± 14  | 92 ± 18 |
| SCD-1                  | 100 ± 31    | 13 ± 4   | 14 ± 3  |
| AMPKα                  | 100 ± 12    | 103 ± 12 | 82 ± 7  |
| PPARγ-related genes    |             |          |         |
| PPARγ                  | 100 ± 7     | 62 ± 7   | 128 ± 27|
| FSP27                  | 100 ± 21    | 95 ± 14  | 178 ± 26|
| CD36                   | 100 ± 12    | 84 ± 8   | 165 ± 27|
| Adipin                 | 100 ± 23    | 43 ± 17  | 204 ± 48|
| Values represent mean ± SEM (n = 5 per group).  
a Significantly different (P < 0.05) when compared with control ASO.  
b Significantly different (P < 0.05) when compared with control ASO treatment.
that overexpression of FSP27 in liver-specific PPARγ−/− mice partially restored hepatic TG accumulation (37). Recent evidence indicates that FSP27 facilitates lipid droplet fusion and expansion (38, 39), which in turn reduces lipolytic activity by limiting lipolytic enzymes (i.e., HSL and ATGL) access to substrate. This reduces TG turnover from lipid droplets, which causes accumulation of lipid within the droplet. In the MTP ASO-treated animals, hepatic FSP27 mRNA expression and lipid droplet size were increased relative to controls and apoB ASO-treated animals. It is possible that the elevated FSP27 expression in MTP ASO-treated animals is shunting the TG normally exported in VLDL particles away from the fatty acid oxidation pathway and into lipid droplets where the TG cannot be mobilized. Therefore, differential effects on both fatty acid synthesis and lipid droplet morphology may help explain the difference in liver TG levels observed between high dose apoB and MTP ASO treatment.

In summary, although apoB and MTP play central roles in hepatic lipoprotein secretion, pharmacological suppression of these proteins leads to distinct differences in metabolic sequelae. Although there were similar reductions in hepatic TG secretion after 6 weeks of ASO treatment, MTP ASO-treated mice accumulated significantly more hepatic TG than apoB ASO-treated mice. Our data suggest that this is likely due to the complex, multiphasic interplay of factors including decreased lipogenesis and changes in lipid droplet metabolism, as exemplified by reductions in hepatic lipid droplet size and FSP27 mRNA expression with apoB ASO treatment relative to MTP ASO treatment.

The authors thank Drs. Stanley T. Crooke, Brett Monia, Michael McCaleb, Brenda Baker, Walter Singleton, and Richard Geary for helpful discussions and review of the manuscript and Yuhong Jiang for technical assistance in Oil Red O staining of liver and intestine.

REFERENCES
1. Heron, M. 2007. Deaths: leading causes for 2004. Natl. Vital Stat. Rep. 56: 1–05.
2. LaRosa, J. C. 2007. Low-density lipoprotein cholesterol reduction: the end is more important than the means. Am. J. Cardiol. 100: 240–242.
3. Baileyt, C. A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366:1267–1278.

4. Amr, M. J. 2007. The safety of statins in clinical practice. Atheroscl. Suppl. 2:19–23.

5. Stein, E. 2002. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Atheroscler. Suppl. 3:137–1351.

6. Lilly, S. M., and D. J. Rader. 2006. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin. Investig. Drugs. 15:1357–1351.

7. Farese, R. V., Jr., S. L. Ruland, L. M. Flynn, R. P. Stokowski, and S. P. Kuss, T. W. Kim, A. Hong, T. A. Watanabe, H. J. Gaus, and R. S. Geary. 2007. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35:460–468.

23. Haghparast, M., D. Wilder, and J. B. Moberly. 1996. Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (Hep 3B). J. Lipid Res. 37:1468–1480.

24. Nicodeme, E., F. Benoist, R. McLeod, Z. Yao, J. Scott, C. C. Shoulders, and T. Grand-Perret. 1999. Identification of domains in apolipoprotein B100 that confer a high requirement for the microsomal triglyceride transfer protein. J. Biol. Chem. 274:1986–1993.

25. Raabe, M., M. M. Veniant, M. A. Sullivan, C. H. Zlot, J. Bjorkgren, L. B. Nielsen, J. S. Wong, R. L. Hamilton, and S. G. Young. 1999. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J. Clin. Invest. 103:1287–1298.

26. Nishino, N., Y. Tamori, S. Tateya, T. Kawaguchi, T. Shibakusa, W. Mizuno, K. Inoue, R. Kitazawa, S. Kitazawa, Y. Matsuaki, et al. 2008. FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J. Clin. Invest. 118:2808–2821.

27. Miyazaki, M., M. T. Flowers, H. Sampaik, K. Chu, C. Oetzlerberger, X. Liu, and J. M. Niumbi. 2007. Hepatic stearyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab. 6:484–496.

28. Yu, S., K. Matsusue, P. Kashiwab, W. Q. Cao, V. Veldandi, A. V. Veldandi, M. S. Rao, F. J. Gonzalez, and J. K. Reddy. 2003. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma (PPARgamma) overexpression. J. Biol. Chem. 278:498–505.

29. Hodson, L., and K. N. Frayn. 2011. Hepatic fatty acid partitioning. Curr. Opin. Lipidol. 22:216–224.

30. Browning, J., D., and J. D. Horton. 2004. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114:147–152.

31. Hardie, D. G., and D. A. Pan. 2002. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans. 30:1061–1070.

32. Tremblay-Mercier, J., D. Tessier, M. Plourde, M. Fortier, D. Lorrain, and S. C. Cunnane. 2010. Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects. J. Pharmacol. Exp. Ther. 334:341–346.

33. Glen, M., G. Haschke, K. Schroeter, A. Penninger, G. Zoller, S. Keil, M. Muller, A. W. Herling, and D. Schmoll. 2011. Stimulation of fat oxidation, but no sustained reduction of hepatic lipids by prolonged pharmacological inhibition of acetyl CoA carboxylase. Horm. Metab. Res. 43:601–606.

34. Savage, D., B., C. S. Choi, V. T. Samuel, Z. X. Liu, D. Zhang, A. Wang, X. M. Zhang, G. W. Cline, X. X. Yu, J. G. Geisler, et al. 2006. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylase 1 and 2. J. Clin. Invest. 116:1468–1479.

35. Lin, X., G. Schonfeld, P. Yue, and Z. Chen. 2002. Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B388.9 mutation. Antioxid. Redox. Signal Vasc. Biol. 22:476–482.

36. Zhong, S., A. L. Magnolo, M. Sundaram, H. Zhou, E. F. Yao, E. Di Leo, P. Loria, S. Wang, M. Bani-Mirza, L. Wang, et al. 2010. Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B. J. Biol. Chem. 285:6453–6464.

37. Matsusue, K., T. Kusakabe, T. Noguchi, S. Takiguchi, T. Suzuki, S. Yamano, and F. J. Gonzalez. 2008. Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. J. Lipid Res. 49:302–311.

38. Gong, J., Z. Sun, L. Wu, W. Xu, N. Schieber, D. Xu, G. Shui, H. Yang, R. G. Parson, and P. Li. 2011. Fsp27 promotes lipid droplet growth by lipid exchange and transfer at lipid droplet contact sites. J. Cell Biol. 195:953–963.

39. Jambumathan, S., J. Yin, W. Khan, Y. Tamori, and V. Puri. 2011. Fsp27 promotes lipid droplet clustering and then fusion to regulate triglyceride accumulation. PLoS ONE. 6:e28614.